基本信息

产品名称	PDPK1 Mouse mAb
别名	PDPK1 小鼠单克隆抗体 \| PDPK1 小鼠单抗
英文别名	EC 2.7.11.1 \| hPDK1
规格或纯度	ExactAb™, Validated, Carrier Free, 1.0mg/mL
宿主种属	小鼠(Mouse)
特异性	PDPK1
种属反应性	人(Human),大鼠(Rat),小鼠(Mouse)
免疫原	Purified recombinant fragment of human PDPK1 (AA: 457-556) expressed in E. Coli.
阳性对照	WB: C6, K562, NIH/3T3 and MCF7 cell lysates. Flow: HeLa cells. ICC/IF: HeLa cells.
偶联	Unconjugated

产品属性

克隆类型	单克隆抗体
克隆号	3H3D9
Format	Whole IgG
亚型	IgG1
轻链亚型	kappa
SDS-PAGE	150 kDa
纯化方法	Protein G purified
物理外观	Liquid
储存缓冲液	Purified antibody in 1xPBS with 0.05% sodium azide
防腐剂	0.05% sodium azid
浓度	1.0mg/mL
储存温度	-20°C储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	4°C 下运输。在 +4°C 下短期储存（1-2 周）。收货后建议分装。长期储存于 -20°C。避免冷冻/解冻循环。
分子类型	抗体

关联靶点（人）

PDPK1 Tchem 3-磷酸肌醇依赖性蛋白激酶 1(3-phosphoinositide-dependent protein kinase 1) (0 活性数据)

点击查看靶蛋白信息： PDPK1

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Western Blot: PDPK1 Mouse mAb (Ab121091)

PDPK1 Mouse mAb (Ab121091) - Western Blot
All lanes: PDPK1 Mouse mAb (Ab121091) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Mouse IgG H&L (HRP) (Ab138040) at 1/20000 dilution

Predicted band size: 64 kDa
Observed band size: 51- 64 kDa
Exposure time: 113.7 s

ICC/IF: PDPK1 Mouse mAb (Ab121091)

PDPK1 Mouse mAb (Ab121091) - ICC/IF
Immunofluorescence analysis of HeLa cells using PDPK1 Mouse mAb (Ab121091) (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with AF555 phalloidin.

Flow Cytometry: PDPK1 Mouse mAb (Ab121091)

PDPK1 Mouse mAb (Ab121091) - Flow Cytometry
Flow cytometric analysis of HeLa cells using PDPK1 Mouse mAb (Ab121091) (green) and negative control (red).

应用

应用名称	稀释比例
IF/ICC	1/200-1/1000
Flow Cytometry	1/200-1/400
ELISA	1/10000
WB	1/500-1/2000.Predicted molecular weight:63 kDa.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	货号
ZJ24F1012038	分析证书	Ab121091
ZJ23F0700736	分析证书	Ab121091
ZJ23F0700737	分析证书	Ab121091

技术文档和文章

流式细胞术

Categories: 技术文章

探索主题:

流式细胞术

流式细胞仪分析

Categories: 技术文章

探索主题:

前向散射侧向散射二向色滤光片多色流式细胞仪

如何选择和使用抗体 — 一抗

Categories: 技术文章

探索主题:

重组蛋白基因敲除免疫细胞化学

How to choose and use antibodies-primary antibody?

Categories: 技术文章

探索主题:

Recombinant antibody Knockout gene ICC

流式细胞术实验方案

Categories: 实验方案（Protocols）

探索主题:

抗体流式细胞术流式抗体活性染料间接抗体标记

How to choose and use antibodies-primary antibody?

Categories: 技术文章

探索主题:

Recombinant antibody Knockout gene ICC

How to choose and use antibodies-primary antibody?

Categories: 技术文章

探索主题:

Recombinant antibody Knockout gene ICC

采用碘化丙啶DNA染色法进行流式细胞术细胞周期分析

Categories: 实验方案（Protocols）

探索主题:

流式抗体溴化丙锭细胞周期

石蜡样品的免疫组化染色方案（IHC-P）

Categories: 实验方案（Protocols）

探索主题:

单克隆抗体石蜡切片免疫组化染色

How to choose and use antibodies-primary antibody?

Categories: 技术文章

探索主题:

Recombinant antibody Knockout gene ICC

利用甲醇通透法进行流式细胞术

Categories: 实验方案（Protocols）

探索主题:

流式细胞术流式抗体流式实验甲醇通透细胞分选细胞分型免疫研究细胞内抗原检测

Flow Cytometry Using Methanol Permeabilization

Categories: 实验方案（Protocols）

探索主题:

Flow Cytometry FlowCytometry methanolpermeabilization flowcytometryantibodies Cell Sorting Cell Typing Immunology Research Intracellular Antigen Detection

Flow Cytometry Using Methanol Permeabilization

Categories: 实验方案（Protocols）

探索主题:

Flow Cytometry FlowCytometry methanolpermeabilization flowcytometryantibodies Cell Sorting Cell Typing Immunology Research Intracellular Antigen Detection

引用文献

1. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO.. (2002) Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.. J Med Chem, 45 (6): (1300-1312). [PMID:11881999] [10.1021/jm011022e]
2. Jensen CJ, Buch MB, Krag TO, Hemmings BA, Gammeltoft S, Frödin M. (1999) 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1.. J Biol Chem, 274 (38): (27168-76). [PMID:10480933]
3. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.. Curr Biol, 7 (4): (261-9). [PMID:9094314]
4. Nagashima K, Shumway SD, Sathyanarayanan S, Chen AH, Dolinski B, Xu Y, Keilhack H, Nguyen T, Wiznerowicz M, Li L et al.. (2011) Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.. J Biol Chem, 286 (8): (6433-48). [PMID:21118801]
5. Biondi RM, Komander D, Thomas CC, Lizcano JM, Deak M, Alessi DR, van Aalten DM. (2002) High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site.. EMBO J, 21 (16): (4219-28). [PMID:12169624]
6. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P et al.. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation.. Nat Chem Biol, 2 (2): (95-102). [PMID:16415863]
7. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A et al.. (2006) N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.. J Med Chem, 49 (22): (6465-88). [PMID:17064066]
8. Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P et al.. (2006) 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.. J Med Chem, 49 (24): (7247-51). [PMID:17125279]
9. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.. Nat Chem Biol, 4 (11): (691-9). [PMID:18849971]
10. Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, Zhu D, Biroc SL, Alicke B, Bryant J, Yuan S et al.. (2005) Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.. J Biol Chem, 280 (20): (19867-74). [PMID:15772071]
11. Medina JR, Becker CJ, Blackledge CW, Duquenne C, Feng Y, Grant SW, Heerding D, Li WH, Miller WH, Romeril SP et al.. (2011) Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.. J Med Chem, 54 (6): (1871-95). [PMID:21341675]
12. Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R et al.. (2010) Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.. Mol Cancer Ther, 9 (3): (706-17). [PMID:20197390]
13. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al.. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).. Blood, 114 (14): (2984-92). [PMID:19654408]
14. Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK, Chen CS. (2011) Identification and characterization of a novel integrin-linked kinase inhibitor.. J Med Chem, 54 (18): (6364-74). [PMID:21823616]
15. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM. (2009) Inhibitor hijacking of Akt activation.. Nat Chem Biol, 5 (7): (484-93). [PMID:19465931]
16. Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M et al.. (2015) Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.. J Med Chem, 58 (17): (6875-98). [PMID:26222319]
17. Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J et al.. (2011) Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 21 (21): (6258-63). [PMID:21958547]
18. Mora A, Komander D, van Aalten DM, Alessi DR. (2004) PDK1, the master regulator of AGC kinase signal transduction.. Semin Cell Dev Biol, 15 (2): (161-70). [PMID:15209375]
19. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640]
20. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al.. (2015) Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.. J Med Chem, 58 (21): (8373-86). [PMID:26505898]
21. Pippione AC, Sainas S, Federico A, Lupino E, Piccinini M, Kubbutat M, Contreras JM, Morice C, Barge A, Ducime A et al.. (2018) N-Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK.. Medchemcomm, 9 (6): (963-968). [PMID:30108985] [10.1039/C8MD00068A]
22. Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C et al.. (2006) Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.. J Med Chem, 49 (13): (3857-71). [PMID:16789742]
23. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E et al.. (2020) Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.. J Med Chem, [PMID:32787110] [10.1021/acs.jmedchem.0c00936]
24. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H. (2018) A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.. Eur J Med Chem, 144 (1-28). [PMID:29247857]
25. Erki Enkvist, Darja Lavogina, Gerda Raidaru, Angela Vaasa, Indrek Viil, Marje Lust, Kaido Viht, Asko Uri,. (2006-11-28) Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases.. Journal of medicinal chemistry, 49 ((24)): ( 7150-7159 ). [PMID:17125267]
26. Seunghee Hong,Jinhee Kim,Sun-Mi Yun,Hyunseung Lee,Yoonsu Park,Soon-Sun Hong,Sungwoo Hong. (2013-04-23) Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.. Journal of medicinal chemistry, 56 ((9)): (3531-3545). [PMID:23600806]
27. Sung Hee Hwang, Aaron T Wecksler, Guodong Zhang, Christophe Morisseau, Long V Nguyen, Samuel H Fu, Bruce D Hammock,. (2013-06-04) Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.. Bioorganic & medicinal chemistry letters, 23 ((13)): ( 3732-3737 ). [PMID:23726028]
28. Iris Z Uras,Thomas List,Sebastian M B Nijman. (2012-02-22) Ubiquitin-specific protease 4 inhibits mono-ubiquitination of the master growth factor signaling kinase PDK1.. PloS one, 7 ((2)): (e31003-e31003). [PMID:22347420]
29. Pevarello P, Brasca MG, Amici R, Orsini P, Traquandi G, Corti L, Piutti C, Sansonna P, Villa M, Pierce BS, Pulici M, Giordano P, Martina K, Fritzen EL, Nugent RA, Casale E, Cameron A, Ciomei M, Roletto F, Isacchi A, Fogliatto G, Pesenti E, Pastori W, Marsiglio A, Leach KL, Clare PM, Fiorentini F, Varasi M, Vulpetti A, Warpehoski MA.. (2004) 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.. J Med Chem, 47 (13): (3367-3380). [PMID:15189033] [10.1021/jm031145u]
30. Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Liu B, Nelson LT, Johnson EF, Wang S, Pederson T, Gum RJ, Clampit JE, Haasch DL, Abad-Zapatero C, Fry EH, Rondinone C, Trevillyan JM, Sham HL, Liu G.. (2006) Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.. J Med Chem, 49 (15): (4455-4458). [PMID:16854050] [10.1021/jm060465l]
31. Chao WR, Yean D, Amin K, Green C, Jong L.. (2007) Computer-aided rational drug design: a novel agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block Akt signaling.. J Med Chem, 50 (15): (3412-3415). [PMID:17602463] [10.1021/jm070040e]
32. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M.. (2007) Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice.. J Med Chem, 50 (23): (5579-5588). [PMID:17929792] [10.1021/jm061449r]
33. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P.. (2008) Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.. J Med Chem, 51 (21): (6642-6645). [PMID:18834107] [10.1021/jm800986w]
34. Shomin CD, Meyer SC, Ghosh I.. (2009) Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling.. Bioorg Med Chem, 17 (17): (6196-6202). [PMID:19674907] [10.1016/j.bmc.2009.07.056]
35. Wee XK, Yeo WK, Zhang B, Tan VB, Lim KM, Tay TE, Go ML.. (2009) Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.. Bioorg Med Chem, 17 (21): (7562-7571). [PMID:19783149] [10.1016/j.bmc.2009.09.008]
36. Deng X, Lim SM, Zhang J, Gray NS.. (2010) Broad spectrum alkynyl inhibitors of T315I Bcr-Abl.. Bioorg Med Chem Lett, 20 (14): (4196-4200). [PMID:20541934] [10.1016/j.bmcl.2010.05.043]
37. Angiolini M, Banfi P, Casale E, Casuscelli F, Fiorelli C, Saccardo MB, Silvagni M, Zuccotto F.. (2010) Structure-based optimization of potent PDK1 inhibitors.. Bioorg Med Chem Lett, 20 (14): (4095-4099). [PMID:20621725] [10.1016/j.bmcl.2010.05.070]
38. Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.. (2011) Potent and selective thiophene urea-templated inhibitors of S6K.. Bioorg Med Chem Lett, 21 (2): (849-852). [PMID:21185721] [10.1016/j.bmcl.2010.11.069]
39. Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, Tóth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I.. (2011) Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.. Bioorg Med Chem Lett, 21 (1): (315-319). [PMID:21112785] [10.1016/j.bmcl.2010.11.010]
40. Ren X, Duan L, He Q, Zhang Z, Zhou Y, Wu D, Pan J, Pei D, Ding K, Ding K.. (2010) Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.. ACS Med Chem Lett, 1 (9): (454-459). [PMID:24900231] [10.1021/ml100146z]
41. De SK, Barile E, Chen V, Stebbins JL, Cellitti JF, Machleidt T, Carlson CB, Yang L, Dahl R, Pellecchia M.. (2011) Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase.. Bioorg Med Chem, 19 (8): (2582-2588). [PMID:21458276] [10.1016/j.bmc.2011.03.017]
42. Poulsen A, Blanchard S, Soh CK, Lee C, Williams M, Wang H, Dymock B.. (2012) Structure-based design of PDK1 inhibitors.. Bioorg Med Chem Lett, 22 (1): (305-307). [PMID:22119465] [10.1016/j.bmcl.2011.11.006]
43. Yang W, AbdulHameed MD, Hamza A, Zhan CG.. (2012) New inhibitor of 3-phosphoinositide dependent protein kinase-1 identified from virtual screening.. Bioorg Med Chem Lett, 22 (4): (1629-1632). [PMID:22266037] [10.1016/j.bmcl.2011.12.121]
44. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B.. (2012) Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.. J Med Chem, 55 (9): (4407-4424). [PMID:22533818] [10.1021/jm300309a]
45. Leahy JW, Buhr CA, Johnson HW, Kim BG, Baik T, Cannoy J, Forsyth TP, Jeong JW, Lee MS, Ma S, Noson K, Wang L, Williams M, Nuss JM, Brooks E, Foster P, Goon L, Heald N, Holst C, Jaeger C, Lam S, Lougheed J, Nguyen L, Plonowski A, Song J, Stout T, Wu X, Yakes MF, Yu P, Zhang W, Lamb P, Raeber O.. (2012) Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.. J Med Chem, 55 (11): (5467-5482). [PMID:22548342] [10.1021/jm300403a]
46. Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N.. (2012) Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.. Bioorg Med Chem Lett, 22 (14): (4613-4618). [PMID:22726925] [10.1016/j.bmcl.2012.05.090]
47. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS.. (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.. Bioorg Med Chem Lett, 22 (17): (5625-5629). [PMID:22863203] [10.1016/j.bmcl.2012.06.104]
48. Amombo GM, Kramer T, Lo Monte F, Göring S, Fach M, Smith S, Kolb S, Schubenel R, Baumann K, Schmidt B.. (2012) Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3.. Bioorg Med Chem Lett, 22 (24): (7634-7640). [PMID:23107479] [10.1016/j.bmcl.2012.10.016]
49. Brown A, Shi Q, Moore TW, Yoon Y, Prussia A, Maddox C, Liotta DC, Shim H, Snyder JP.. (2013) Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.. J Med Chem, 56 (9): (3456-3466). [PMID:23550937] [10.1021/jm4002692]
50. Liu GZ, Xu HW, Wang P, Lin ZT, Duan YC, Zheng JX, Liu HM.. (2013) Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones.. Eur J Med Chem, 65 (323-336). [PMID:23735281] [10.1016/j.ejmech.2013.04.062]
51. Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB.. (2014) Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.. Bioorg Med Chem Lett, 24 (12): (2635-2639). [PMID:24813737] [10.1016/j.bmcl.2014.04.068]
52. Yan R, Chuang HC, Kapuriya N, Chou CC, Lai PT, Chang HW, Yang CN, Kulp SK, Chen CS.. (2015) Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors.. J Med Chem, 58 (5): (2290-2298). [PMID:25689347] [10.1021/jm501751b]
53. Rettenmaier TJ, Fan H, Karpiak J, Doak A, Sali A, Shoichet BK, Wells JA.. (2015) Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking.. J Med Chem, 58 (20): (8285-8291). [PMID:26443011] [10.1021/acs.jmedchem.5b01216]
54. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L.. (2015) Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.. Bioorg Med Chem, 23 (21): (7000-7006). [PMID:26455654] [10.1016/j.bmc.2015.09.038]
55. Sestito S, Nesi G, Daniele S, Martelli A, Digiacomo M, Borghini A, Pietra D, Calderone V, Lapucci A, Falasca M, Parrella P, Notarangelo A, Breschi MC, Macchia M, Martini C, Rapposelli S.. (2015) Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.. Eur J Med Chem, 105 (274-288). [PMID:26498573] [10.1016/j.ejmech.2015.10.020]
56. Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H, Okabe T, Nagano T.. (2015) Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.. Bioorg Med Chem Lett, 25 (24): (5687-5693). [PMID:26547690] [10.1016/j.bmcl.2015.10.098]
57. Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J.. (2016) 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.. J Med Chem, 59 (4): (1388-1409). [PMID:26741168] [10.1021/acs.jmedchem.5b01635]
58. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J.. (2016) Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.. Bioorg Med Chem Lett, 26 (5): (1443-1451). [PMID:26852363] [10.1016/j.bmcl.2016.01.062]
59. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.. (2016) Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.. J Med Chem, 59 (8): (3886-3905). [PMID:27010810] [10.1021/acs.jmedchem.6b00087]
60. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800] [10.1016/j.bmcl.2016.04.079]
61. Laufer R, Li SW, Liu Y, Ng G, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Mao G, Plotnikova O, Awrey DE, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW.. (2016) Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.. Bioorg Med Chem Lett, 26 (15): (3562-3566). [PMID:27335255] [10.1016/j.bmcl.2016.06.021]
62. Kumar V, Guru SK, Jain SK, Joshi P, Gandhi SG, Bharate SB, Bhushan S, Bharate SS, Vishwakarma RA.. (2016) A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties.. Bioorg Med Chem Lett, 26 (15): (3457-3463). [PMID:27363938] [10.1016/j.bmcl.2016.06.046]
63. Chen Y, Zheng Y, Jiang Q, Qin F, Zhang Y, Fu L, He G.. (2017) Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells.. Eur J Med Chem, 127 (997-1011). [PMID:27839788] [10.1016/j.ejmech.2016.11.009]
64. Wagman AS, Boyce RS, Brown SP, Fang E, Goff D, Jansen JM, Le VP, Levine BH, Ng SC, Ni ZJ, Nuss JM, Pfister KB, Ramurthy S, Renhowe PA, Ring DB, Shu W, Subramanian S, Zhou XA, Shafer CM, Harrison SD, Johnson KW, Bussiere DE.. (2017) Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3.. J Med Chem, 60 (20): (8482-8514). [PMID:29016121] [10.1021/acs.jmedchem.7b00922]
65. Gouda AM, Abdelazeem AH, Omar HA, Abdalla AN, Abourehab MAS, Ali HI.. (2017) Pyrrolizines: Design, synthesis, anticancer evaluation and investigation of the potential mechanism of action.. Bioorg Med Chem, 25 (20): (5637-5651). [PMID:28916158] [10.1016/j.bmc.2017.08.039]
66. Malínková V, Řezníčková E, Jorda R, Gucký T, Kryštof V.. (2017) Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1.. Bioorg Med Chem, 25 (24): (6523-6535). [PMID:29089259] [10.1016/j.bmc.2017.10.032]
67. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.. (2018) Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.. Bioorg Med Chem, 26 (3): (590-602). [PMID:29289448] [10.1016/j.bmc.2017.12.020]
68. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C.. (2018) Effects of rigidity on the selectivity of protein kinase inhibitors.. Eur J Med Chem, 146 (519-528). [PMID:29407977] [10.1016/j.ejmech.2018.01.053]
69. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J.. (2018) Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.. Eur J Med Chem, 150 (366-384). [PMID:29544149] [10.1016/j.ejmech.2018.03.003]
70. He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG.. (2018) Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells.. Bioorg Med Chem, 26 (14): (3899-3908). [PMID:29921474] [10.1016/j.bmc.2018.06.010]
71. Lovering F, Morgan P, Allais C, Aulabaugh A, Brodfuehrer J, Chang J, Coe J, Ding W, Dowty H, Fleming M, Frisbie R, Guzova J, Hepworth D, Jasti J, Kortum S, Kurumbail R, Mohan S, Papaioannou N, Strohbach JW, Vincent F, Lee K, Zapf CW.. (2018) Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors.. Eur J Med Chem, 145 (606-621). [PMID:29348070] [10.1016/j.ejmech.2017.12.041]
72. Gao JB, Yang SJ, Yan ZR, Zhang XJ, Pu DB, Wang LX, Li XL, Zhang RH, Xiao WL.. (2018) Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.. J Nat Prod, 81 (4): (998-1006). [PMID:29578342] [10.1021/acs.jnatprod.7b01082]
73. Zhang D, Tong D, Yang D, Sun J, Zhang F, Zhao G.. (2018) Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant.. Medchemcomm, 9 (8): (1340-1350). [PMID:30151089] [10.1039/C8MD00197A]
74. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.. (2018) Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.. Bioorg Med Chem Lett, 28 (20): (3356-3362). [PMID:30227946] [10.1016/j.bmcl.2018.09.006]
75. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q.. (2018) Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.. Eur J Med Chem, 158 (896-916). [PMID:30253346] [10.1016/j.ejmech.2018.09.025]
76. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M.. (2019) Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis.. ACS Med Chem Lett, 10 (9): (1272-1278). [PMID:31531196] [10.1021/acsmedchemlett.9b00142]
77. Zhang Q, Hu X, Wan G, Wang J, Li L, Wu X, Liu Z, Yu L.. (2019) Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer.. Eur J Med Chem, 184 (111728-111728). [PMID:31610375] [10.1016/j.ejmech.2019.111728]
78. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z.. (2019) Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.. Eur J Med Chem, 171 (221-234). [PMID:30925338] [10.1016/j.ejmech.2019.03.039]
79. Liang X, Zang J, Li X, Tang S, Huang M, Geng M, Chou CJ, Li C, Cao Y, Xu W, Liu H, Zhang Y.. (2019) Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.. J Med Chem, 62 (8): (3898-3923). [PMID:30901208] [10.1021/acs.jmedchem.8b01597]
80. Zhao L, Li Y, Wang Y, Qiao Z, Miao Z, Yang J, Huang L, Tian C, Li L, Chen D, Yang S.. (2019) Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models.. J Med Chem, 62 (23): (10691-10710). [PMID:31693351] [10.1021/acs.jmedchem.9b01143]
81. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS.. (2017) Discovery of a potent dual ALK and EGFR T790M inhibitor.. Eur J Med Chem, 136 (497-510). [PMID:28528303] [10.1016/j.ejmech.2017.04.079]
82. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY.. (2019) Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3.. Eur J Med Chem, 168 (58-77). [PMID:30798053] [10.1016/j.ejmech.2018.12.063]
83. Heider F, Ansideri F, Tesch R, Pantsar T, Haun U, Döring E, Kudolo M, Poso A, Albrecht W, Laufer SA, Koch P.. (2019) Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.. Eur J Med Chem, 175 (309-329). [PMID:31096153] [10.1016/j.ejmech.2019.04.035]
84. Yueh C, Rettenmaier J, Xia B, Hall DR, Alekseenko A, Porter KA, Barkovich K, Keseru G, Whitty A, Wells JA, Vajda S, Kozakov D.. (2019) Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases.. J Med Chem, 62 (14): (6512-6524). [PMID:31274316] [10.1021/acs.jmedchem.9b00089]
85. Ikegashira K, Ikenogami T, Yamasaki T, Oka T, Hase Y, Miyagawa N, Inagaki K, Kawahara I, Koga Y, Hashimoto H.. (2019) Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952.. Bioorg Med Chem Lett, 29 (7): (873-877). [PMID:30755337] [10.1016/j.bmcl.2019.02.006]
86. Yang J,Chen K,Zhang G,Yang QY,Li YS,Huang SZ,Wang YL,Yang W,Jiang XJ,Yan HX,Zhu JQ,Xiang R,Luo YF,Li WM,Wei YQ,Li LL,Yang SY. (2018) Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.. Eur J Med Chem, 143 (1148-1164). [PMID:29133048] [10.1016/j.ejmech.2017.09.018]
87. Alessi, D R DR and 11 more authors.. (1997) 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase.. Current biology : CB, (1): [PMID:9368760]
88. Pullen, N N and 6 more authors.. (1998) Phosphorylation and activation of p70s6k by PDK1.. Science (New York, N.Y.), (30): [PMID:9445476]
89. Stephens, L L and 11 more authors.. (1998) Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B.. Science (New York, N.Y.), (30): [PMID:9445477]
90. Anderson, K E KE, Coadwell, J J, Stephens, L R LR and Hawkins, P T PT.. (1998) Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B.. Current biology : CB, (4): [PMID:9637919]
91. Chou, M M MM and 8 more authors.. (1998) Regulation of protein kinase C zeta by PI 3-kinase and PDK-1.. Current biology : CB, (24): [PMID:9768361]
92. Balendran, A A and 7 more authors.. (1999) PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2.. Current biology : CB, (22): [PMID:10226025]
93. Paradis, S S, Ailion, M M, Toker, A A, Thomas, J H JH and Ruvkun, G G.. (1999) A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in Caenorhabditis elegans.. Genes & development, (1): [PMID:10364160]
94. Casamayor, A A, Morrice, N A NA and Alessi, D R DR.. (1999) Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo.. The Biochemical journal, (1): [PMID:10455013]
95. King, C C CC and 6 more authors.. (2000) p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1).. The Journal of biological chemistry, (29): [PMID:10995762]
96. Park, J J and 5 more authors.. (2001) Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 and their role in regulating kinase activity.. The Journal of biological chemistry, (5): [PMID:11481331]
97. Scheid, Michael P MP, Marignani, Paola A PA and Woodgett, James R JR.. (2002) Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B.. Molecular and cellular biology, [PMID:12167717]
98. Sato, Saori S, Fujita, Naoya N and Tsuruo, Takashi T.. (2002) Regulation of kinase activity of 3-phosphoinositide-dependent protein kinase-1 by binding to 14-3-3.. The Journal of biological chemistry, (18): [PMID:12177059]
99. Taniyama, Yoshihiro Y and 8 more authors.. (2003) Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates focal adhesions.. Molecular and cellular biology, [PMID:14585963]
100. Nilsen, Trine T and 5 more authors.. (2004) Peroxisomal targeting as a tool for assaying potein-protein interactions in the living cell: cytokine-independent survival kinase (CISK) binds PDK-1 in vivo in a phosphorylation-dependent manner.. The Journal of biological chemistry, (6): [PMID:14604990]
101. Komander, David D and 10 more authors.. (2004) Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1.. Structure (London, England : 1993), [PMID:14962382]
102. King, Charles C CC and Newton, Alexandra C AC.. (2004) The adaptor protein Grb14 regulates the localization of 3-phosphoinositide-dependent kinase-1.. The Journal of biological chemistry, (3): [PMID:15210700]
103. Martin, Joel J and 121 more authors.. (2004) The sequence and analysis of duplication-rich human chromosome 16.. Nature, (23): [PMID:15616553]
104. Komander, David D, Kular, Gursant G, Deak, Maria M, Alessi, Dario R DR and van Aalten, Daan M F DM.. (2005) Role of T-loop phosphorylation in PDK1 activation, stability, and substrate binding.. The Journal of biological chemistry, (13): [PMID:15741170]
105. Scheid, Michael P MP, Parsons, Michael M and Woodgett, James R JR.. (2005) Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation.. Molecular and cellular biology, [PMID:15743829]
106. Tong, Zhimin Z and 5 more authors.. (2005) Neutrophil gelatinase-associated lipocalin as a survival factor.. The Biochemical journal, (15): [PMID:16060857]
107. Tanaka, Hiroshi H, Fujita, Naoya N and Tsuruo, Takashi T.. (2005) 3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling.. The Journal of biological chemistry, (9): [PMID:16207722]
108. Seong, Hyun-A HA, Jung, Haiyoung H, Choi, Hueng-Sik HS, Kim, Kyong-Tai KT and Ha, Hyunjung H.. (2005) Regulation of transforming growth factor-beta signaling and PDK1 kinase activity by physical interaction between PDK1 and serine-threonine kinase receptor-associated protein.. The Journal of biological chemistry, (30): [PMID:16251192]
109. Fiory, Francesca F and 11 more authors.. (2005) Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the insulin receptor is necessary for insulin metabolic signaling.. Molecular and cellular biology, [PMID:16314505]
110. Li, Junan J and 5 more authors.. (2006) A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, [PMID:16455452]
111. Tseng, Ping-Hui PH and 10 more authors.. (2006) Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.. Molecular pharmacology, [PMID:16887935]
112. Seong, Hyun-A HA, Jung, Haiyoung H, Kim, Kyong-Tai KT and Ha, Hyunjung H.. (2007) 3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth factor-beta-induced signaling in a kinase-dependent manner through physical interaction with Smad proteins.. The Journal of biological chemistry, (20): [PMID:17327236]
113. Primo, Luca L and 6 more authors.. (2007) Essential role of PDK1 in regulating endothelial cell migration.. The Journal of cell biology, (26): [PMID:17371830]
114. Yang, Keum-Jin KJ and 15 more authors.. (2008) Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain binding.. The Journal of biological chemistry, (18): [PMID:18024423]
115. Kurata, Atsuo A, Katayama, Ryohei R, Watanabe, Toshiki T, Tsuruo, Takashi T and Fujita, Naoya N.. (2008) TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling.. Cancer science, [PMID:18616680]
116. Lim, Wee Guan WG and 14 more authors.. (2008) The C-terminus of PRK2/PKNgamma is required for optimal activation by RhoA in a GTP-dependent manner.. Archives of biochemistry and biophysics, (15): [PMID:18835241]
117. Alajajian, Betty B BB, Fletcher, Lauren L, Isgor, Elif E, Jimenez, David F DF and Digicaylioglu, Murat M.. (2009) IGF-I regulated phosphorylation and translocation of PDK-1 in neurons.. Neuroreport, (22): [PMID:19276999]
118. Sephton, C F CF and 5 more authors.. (2009) The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is dependent on its association with the protein tyrosine phosphatase SHP-1.. Cellular signalling, [PMID:19591923]
119. Mayya, Viveka V and 7 more authors.. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.. Science signaling, (18): [PMID:19690332]
120. Bobkova, Ekaterina V EV and 9 more authors.. (2010) Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening.. The Journal of biological chemistry, (11): [PMID:20385558]
121. Masters, Thomas A TA and 7 more authors.. (2010) Regulation of 3-phosphoinositide-dependent protein kinase 1 activity by homodimerization in live cells.. Science signaling, (26): [PMID:20978239]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

货号 (SKU)	包装规格	是否现货
Ab121091-10μl	10μl	现货
Ab121091-50μL	50μL	现货
Ab121091-100μL	100μL	现货
Ab121091-1mL	1ml	期货

PDPK1 Mouse mAb

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

应用

质检证书（CoA,COO,BSE/TSE 和分析图谱)

技术文档和文章

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

PDPK1 Mouse mAb

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

应用

质检证书（CoA,COO,BSE/TSE 和分析图谱)

技术文档和文章

相关产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器